Nelson Vergel
Founder, ExcelMale.com
VIDEO ANALYSIS BRIEF
Steroids & Testosterone: The Science Behind Anabolic Therapies
with Nelson Vergel
The Dr. Gabrielle Lyon Show • Episode 144 | March 18, 2025 | 1 hr 36 min
Overview
Nelson Vergel — chemical engineer, HIV survivor, and founder of ExcelMale.com — joins Dr. Gabrielle Lyon for a deep, clinically grounded 96-minute conversation on anabolic therapies. Nelson recounts surviving AIDS-related wasting in the 1990s through testosterone and nandrolone, turning personal crisis into a 30-year advocacy career. The episode dismantles media stigma around anabolic agents, carefully distinguishes testosterone, nandrolone, and oxandrolone by mechanism and side-effect profile, and addresses one of today's most urgent crossover issues: GLP-1 medications driving significant lean mass loss. The pair close on hormone monitoring best practices, the expanding role of compounding pharmacies, and why personalized medicine is non-negotiable in hormone management.Key Takeaways
• Anabolic therapies saved Nelson's life — and the science behind them is far more nuanced than media coverage suggests.• Nandrolone and oxandrolone are not interchangeable with testosterone — each has a distinct receptor profile and clinical use case.
• GLP-1 drugs (semaglutide, tirzepatide) cause substantial lean mass loss — anabolics and resistance training are the primary countermeasures.
• Muscle loss is a silent public health crisis — sarcopenia shortens healthspan far more than most chronic diseases, yet it is largely ignored.
• Routine blood monitoring (hematocrit, PSA, estradiol, lipids) is essential — 'set and forget' TRT is one of the most common and dangerous mistakes.
• Compounding pharmacies provide critical access to non-FDA-standard formulations — subcutaneous injections and customized dosing are key innovations.
• Personalized medicine over population-level guidelines — individual biomarkers, goals, and tolerance must drive every hormone protocol decision.
Episode Timestamps
00:00 | Intro & Forever Strong Summit Dr. Lyon welcomes Nelson and frames the conversation |
02:21 | Meet Nelson Vergel Chemical engineer, author, founder of ExcelMale & DiscountedLabs |
04:34 | HIV diagnosis → hormone advocacy Mid-1980s diagnosis, wasting syndrome, discovery of testosterone + nandrolone |
08:12 | Testosterone & anabolics in muscle Mechanism of androgen action on satellite cells and protein synthesis |
14:42 | Stigma & misconceptions Why anabolics are conflated with doping and how that harms patients |
18:01 | Nandrolone vs oxandrolone vs T Comparative androgenicity, anabolic ratios, side-effect profiles |
24:04 | GLP-1 medications & lean mass loss How semaglutide/tirzepatide erode muscle and mitigation strategies |
30:17 | Resistance training as essential Why exercise is non-negotiable alongside any hormone or GLP-1 protocol |
35:07 | Muscle loss as a public health crisis Sarcopenia epidemiology, economic burden, and policy gap |
41:55 | Safe hormone monitoring Labs to run: hematocrit, PSA, estradiol, SHBG, lipids |
48:00 | Compounding pharmacies & HRT access SubQ injection techniques, customized doses, regulatory landscape |
52:47 | Future of anabolic therapies Pipeline agents, sarcopenia trials, SARMs, broader clinical adoption |
1:02:00 | Personalized medicine in HRT Why cookie-cutter dosing fails and how to work with a knowledgeable clinician |
1:09:14 | Final thoughts & resources ExcelMale.com, DiscountedLabs.com, Beyond Testosterone |
Deep Dive — Concepts & Frameworks
1. Anabolic Agent Comparison
The three primary anabolic agents discussed have meaningfully different receptor profiles and clinical niches. Using them interchangeably is a common clinical error.Agent | Androgenicity | Primary use |
Testosterone | High | Hypogonadism, TRT baseline |
Nandrolone | Low | Wasting, joint support, HIV/cancer cachexia |
Oxandrolone | Very low | Burns, pediatric growth, female use |
2. GLP-1 Medications & the Lean Mass Problem
Weight lost on GLP-1 medications (semaglutide, tirzepatide) is approximately 30–40% lean mass without deliberate intervention. This has major implications for long-term metabolic health:• Rapid caloric restriction accelerates muscle catabolism
• Protein intake of ≥1.2g/kg bodyweight is the first-line dietary defense
• Resistance training (3+ sessions/week) is non-negotiable alongside GLP-1 therapy
• Anabolic therapy (TRT or low-dose nandrolone) may be warranted in high-risk patients
• Sarcopenic obesity — losing muscle while retaining fat — is the worst outcome and is underdiagnosed
Key insight: GLP-1 drugs are causing a lean mass crisis in slow motion. The weight-loss number is celebrated without examining what is actually being lost from the body.
3. Safe Hormone Monitoring — Essential Lab Panel
Nelson emphasizes that monitoring is not optional — it is the foundation of responsible hormone therapy. Below are the biomarkers he recommends tracking:Biomarker | Why it matters | Frequency |
Hematocrit | Keep below 50% — monitors polycythemia risk | Every 3–6 months |
Total & Free T | Confirm therapeutic range | 3 mo after change, then 6-mo |
SHBG | Determines free vs bound ratio — key for dosing | With T panel |
Estradiol (sensitive) | Controls libido, bone density, CV function | Every 3–6 months |
PSA | Baseline before TRT, track trend not single value | Annually (or per urologist) |
Lipid panel | Some anabolics adversely affect HDL | Annually |
CBC | Full blood count — detects cytopenias or excess | Annually |
4. TRT Best Practices — Nelson's Core Principles
• Never 'cycle' TRT — it is a lifelong maintenance therapy, not a performance protocol• Use subcutaneous (SubQ) injections in the abdomen for stable, even blood levels and fewer side effects
• Protect fertility by adding HCG to prevent testicular atrophy
• Avoid unverified testosterone boosters — most are ineffective or contain undisclosed substances
• Injection frequency matters more than total dose — more frequent = fewer peaks = fewer side effects
5. Sarcopenia as a Public Health Crisis
• Muscle mass declines approximately 1% per year after age 30–35• Decline accelerates significantly after age 60
• Predicts falls, fractures, metabolic syndrome, and all-cause mortality
• GLP-1 adoption at scale risks accelerating population-level sarcopenia
• No FDA-approved drug currently exists for sarcopenia treatment — a major clinical gap
6. Compounding Pharmacies & Access to HRT
• Provide custom formulations unavailable commercially (e.g., nandrolone, low-dose oxandrolone)• Subcutaneous injection preparations reduce peak-and-valley hormonal fluctuation
• Generally more affordable than brand-name equivalents
• Face increasing FDA scrutiny — use only 503B-regulated facilities for consistent quality
• Critical for women's HRT: low-dose testosterone, topical estradiol/progesterone combinations
Actionable Applications
1. IF ON A GLP-1: Immediately add resistance training (3x/week minimum) and increase protein to ≥1.2g/kg bodyweight. Discuss TRT or nandrolone with a physician if lean mass loss is measurable on DEXA.2. FOR TRT PATIENTS: Insist on a full baseline panel (total T, free T, SHBG, estradiol, hematocrit, PSA, CBC, lipids) before starting — and recheck at 3 months post-initiation, then semi-annually.
3. FOR CLINICIANS: Consider nandrolone decanoate (50–100mg/2 weeks) for patients with catabolic conditions, poor androgen tolerance, or joint concerns. It is severely under-prescribed relative to the evidence base.
4. FOR AFFORDABLE LAB ACCESS: Use DiscountedLabs.com for self-pay panels without a physician order — useful for tracking SHBG, estradiol, and hematocrit between formal appointments.
5. TO REDUCE INJECTION SIDE EFFECTS: Switch from intramuscular (IM) to subcutaneous (SubQ) injections using a 27g 0.5" needle in the abdomen. Smoother absorption, fewer hormonal peaks, lower hematocrit elevation.
6. FOR PATIENT EDUCATION OR CONTENT: Direct audiences to ExcelMale.com (44,000+ members) and the book Beyond Testosterone for evidence-based information accessible to both patients and clinicians.
Key Quotes
"I was handed what most people would consider a death sentence — and I decided to become my own lab rat instead."⏱ 04:34 — Nelson on his HIV diagnosis and path to hormone advocacy
"The stigma around anabolic agents has killed more people than the drugs ever did — patients are denied life-saving treatment because their physician is afraid of a headline."
⏱ 14:42 — on the cost of media stigma
"GLP-1 drugs are causing a lean mass crisis in slow motion. We're celebrating the weight loss number without looking at what we're actually losing."
⏱ 24:04 — on the body-composition problem with GLP-1 drugs
"Muscle is the organ of longevity. You can't buy it at a pharmacy — you have to build it and then protect it."
⏱ 35:07 — on the primacy of skeletal muscle in healthspan
"Set and forget is not a hormone protocol — it is negligence. You must monitor and you must adjust."
⏱ 41:55 — on the non-negotiability of ongoing hormone monitoring
Related Topics to Explore
Based on this episode, the following subjects warrant further study:• Sarcopenia epidemiology & aging — global burden data and trajectory
• GLP-1 body composition outcomes — clinical trial DEXA data
• Nandrolone decanoate protocols — dosing, monitoring, indications
• Oxandrolone in women — safety, efficacy, and off-label applications
• SHBG and free testosterone — why total T can mislead
• 503B compounding pharmacies — regulatory framework and patient safety
• HCG & fertility preservation on TRT — mechanisms and protocols
• Subcutaneous testosterone injection technique — evidence vs IM
• Estradiol management in men on TRT — the case against routine AI use
• Beyond Testosterone (Nelson Vergel, 2023) — full clinical reference
• HIV wasting syndrome history — lessons for oncology and aging
• SARMs research pipeline — selective androgen receptor modulators in development
• Personalized vs population-based TRT guidelines — clinical debate
Resources & Links
Nelson Vergel:• Website: www.nelsonvergel.com
• Forum: www.excelmale.com (44,000+ members)
• Labs: www.discountedlabs.com
• Book: Beyond Testosterone — available on Amazon
Episode:
• YouTube:
• Podcast: The Dr. Gabrielle Lyon Show
Last edited:
